Therapie der renalen Anämie - mit welchem Ziel?

Anämie - chronische Nierenerkrankung - Ziel-Hämoglobinwert - Erythropoietin

anemia - chronic kidney disease - target-hemoglobin - erythropoietin

Literatur

• 1 Astor B C, Mutner P, Levin A, Eustace J A, Coresh J. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988 - 1994).  Arch Intern Med. 2002;  162 1401-1408
• 2 Besarab A, Bolton W K, Browne J K. et al . The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and Epoetin.  N Engl J Med. 1998;  339 584-590
• 3 Drueke T B, Locatelli F, Clyne N. et al . Normalization of hemoglobin level in patients with chronic kidney disease and anemia.  N Engl J Med. 2006;  355 2071-2084
• 4 Eckardt K U. Cardiovascular consequences of renal anaemia and erythropoietin therapy.  Nephrol Dial Transplant. 1999;  14 1317-1323
• 5 Eschbach J, Egrie J C, Downing M R, Browne J K, Adamson J W. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin.   N Engl J Med. 1987;  316 73-78
• 6 Ezekowitz J A. et al . Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure.  Circulation. 2003;  107 223-225
• 7 Hahn E A, Cella D, Chassany O, Fairclough D L, Wong G Y, Hays R DA. Comparison of the Precision of Health-Related Quality of Life Data Relative to Other Clinical Measures.  Mayo ClinProc. 2007;  in press
• 8 Hörl W. Clinical aspects of iron use in the anemia of kidney disease.  J Am Soc Nephrol. 2007;  18 382-393
• 9 Macdougall I, Eckardt K U. Novel strategies for stimulating erythropoiesis and potential new treatments for anemia.  Lancet. 2006;  368 947-953
• 10 Mix T C, Brenner R M, Cooper M E. et al . Rationale - Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease.  Am Heart J. 2005;  149 408-413
• 11 Mohanram A, Zhang Z, Shahinfar S, Keane W F, Brenner B M, Toto R D. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy.  Kidney Int. 2004;  66 1131-1138
• 12 Nangaku M, Eckardt K U. Pathogenesis of renal anemia.  Semin Nephrol. 2006;  26 261-268
• 13 National Kidney Foundation . KDOQI Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin targets.  Am J Kidney Dis. 2007;  in preparation
• 14 Ofsthun N, Labrecque J, Lacson E. et al . The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients.  Kidney Int. 2003;  63 1908-1914
• 15 Parfrey P S, Foley R N, Wittreich B H. et al . Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease.  J Am Soc Nephrol. 2005;  16 2180-2189
• 16 Sarnak M J, Tighiouart H, Manjunath G, MacLeod B, Griffith J, Salem D, Levey A S. Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study.  J Am Coll Cardiol. 2002;  40 27-33
• 17 Singh A K, Szczech L, Tang K L. et al . Correction of anemia with epoetin alfa in chronic kidney disease.  N Engl J Med. 2006;  355 2085-2098
• 18 Volkova N, Arab L. Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients.  Am J Kidney Dis. 2006;  47 24-36